Processa Pharmaceuticals, Inc. to Present at the 8th Annual LD Micro Invitational
LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Processa Pharmaceuticals, Inc. (OTC PINK: PCSA), clinical stage drug development company focused on the treatment of patients with high unmet medical need conditions, today announced that it will be presenting at the 8th annual LD Micro Invitational on Monday, June 4 at 12 /PM PST / 3 PM EST. Dr. David Young (Chief Executive Officer) and Patrick Lin (Chief Business and Strategy Officer) of Processa Pharmaceuticals will be giving the presentation and are available to meet with investors. The Company's presentation will be available to the public to access at http://processapharmaceuticals.com/investors-events.php.
"The event is slated to be our largest Invitational to date," stated Chris Lahiji, President of LD Micro. "When the fires caused the cancellation of our Main Event back in December, we vowed to come back even stronger. This event showcases our firm's ability to attract the most unique and exciting names in micro-cap."
The conference will be held at the Luxe Sunset Bel Air Hotel, will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals. For more information, or to schedule a one-on-one meeting with the Company, please contact David Scher at david@ldmicro.com or call 831.566.6995.
View Processa's profile here: https://www.ldmicro.com/profile/PCSA.
Profiles powered by LD Micro - News Compliments of Accesswire.
About Processa Pharmaceuticals
Processa is a clinical-stage drug development company focused on:
Patients with an illness or condition that have no treatment options, or the present therapy is inadequate (unmet medical need),
Drugs that will improve the survival and/or quality of life of patients, and
Drugs which have some evidence of clinical efficacy/safety whether it be the drug itself or a drug with similar pharmacology.
Processa has acquired one drug shown to be clinically safe that can potentially treat multiple indications. This drug will begin Phase 2 trials in Necrobiosis Lipoidica (gross sales opportunity of over $1B) in 2018. With an experienced team of drug developers and biotech executives, Processa plans to expand its clinical development pipeline in 2018.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
Contact:
Patrick Lin, Chief Business and Strategy Officer
7380 Coca Cola Drive, Suite 106, Hanover, MD 21076
plin@processapharma.com
925.683.3218
SOURCE: Processa Pharmaceuticals, Inc.
